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Objectives The purpose of this study was to determine the independent and additive prognostic value of B-type natriuretic
peptide (BNP) in patients with severe asymptomatic aortic regurgitation and normal left ventricular function.
Background Early surgery could be advisable in selected patients with chronic severe aortic regurgitation, but there are no
uniform criteria to identify candidates who could benefit from this strategy. Assessment of BNP has not been
studied for this purpose.
Methods We prospectively evaluated 294 consecutive patients with severe asymptomatic organic aortic regurgitation and
left ventricular ejection fraction above 55%. The first 160 consecutive patients served as the derivation cohort
and the next 134 patients served as a validation cohort. The combined endpoint was the occurrence of symp-
toms of congestive heart failure, left ventricular dysfunction, or death at follow-up.
Results The endpoint was reached in 45 patients (28%) of the derivation set and in 35 patients (26%) of the validation
cohort. Receiver-operator characteristic curve analysis yielded an optimal cutoff point of 130 pg/ml for BNP that
was able to discriminate between patients at higher risk in both cohorts. BNP was the strongest independent
predictor by multivariate analysis in the derivation set (odds ratio: 6.9 [95% confidence interval: 2.52 to 17.57],
p  0.0001) and the validation set (odds ratio: 6.7 [95% confidence interval: 2.9 to 16.9], p  0.0001).
Conclusions Among patients with severe asymptomatic aortic regurgitation and normal left ventricular function, BNP 130
pg/ml categorizes a subgroup of patients at higher risk. Because of its incremental prognostic value, we believe
BNP assessment should be used in the routine clinical evaluation of these patients. (J Am Coll Cardiol 2011;
58:1705–14) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.016Severe organic aortic regurgitation (AR) is a progressive
disease with a high incidence of events, especially after the
onset of symptoms (1–5). Currently, consideration of sur-
gical treatment in patients with severe AR involves the
presence of symptoms of congestive heart failure (CHF) or
abnormal resting left ventricular (LV) function (1,2,6,7). By
contrast, the decision to intervene in asymptomatic patients
without left ventricular dysfunction (LVD) (“early” surgery)
is a source of ongoing clinical controversy. Early surgical
treatment may be convenient for selected patients, but the
risk of the surgical procedure should be considered against
the risk of sudden death, heart failure, or LVD (1,2).
From the Cardiology Division, Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina. All authors have reported that they have no relationships relevant to the
contents of this paper to disclose.Manuscript received April 19, 2011; revised manuscript received June 30, 2011,
accepted July 26, 2011.In this particular subset of patients, there are no strong
indicators useful for the recommendation of early surgical
intervention (1,2,8). Data have suggested a role for the assess-
ment of serial echocardiographic parameters. Specifically, end-
systolic diameter (ESD) and end-diastolic diameter (EDD), as
well as LV volumes and ejection fraction (EF), have been
found to allow risk stratification in asymptomatic patients
(1–5). Another marker of hemodynamic consequences, the
effective regurgitant orifice area (EROA), has also been shown
to correlate with an adverse outcome (7).
In previous studies (9–11), the measurement of natriuretic
peptides in patients with heart failure has become important.
The B-type natriuretic peptide (BNP) and its inactive
N-terminal pro–B-type natriuretic peptide (NT-proBNP)
both result from the breakdown of proBNP. These hormones
have vasodilator and diuretic effects, are antagonists of the
adrenergic and renin-angiotensin systems, and are released in
response to an increase in myocardial wall stress (WS) (1). The
prognostic value of natriuretic peptides has been assessed in
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BNP in Asymptomatic Severe Aortic Regurgitation October 11 2011:1705–14patients with valve disease, with
inconsistent results and without
information regarding clinical and
echocardiographic data (12,13).
Hence, the purpose of this in-
vestigation was to determine the
additional prognostic value of
baseline BNP level in asymptom-
atic patients with severe AR and
no LVD. Our goal was also to
validate prospectively a cutoff
BNP value for the prediction of
an adverse outcome, and to assess
the prognostic significance of the
changes in the BNP level ob-
served between baseline and 1
year of follow-up.
Methods
Study population. In this single-
center study, we prospectively
evaluated 294 consecutive pa-
tients presenting with chronic se-
vere asymptomatic organic AR
and normal left ventricular per-
formance (EF above 55%).
Applying a splitting tech-
nique, the first 160 consecutive
patients were analyzed as the
derivation set of data (mean age
51  9 years; 64% men; mean
EF 63  5%) and the next 134
consecutive patients as the vali-
dation set (mean age 53  10
years; 65% men; mean EF 64 
6%). In the derivation set, the
etiology of the AR was degener-
ative in 72 patients, congenital
(bicuspid) in 60, rheumatic in 12,
post-endocarditis in 10, and mis-
cellaneous in 6 patients. In the
validation set, these etiologies
were observed in 65, 51, 9, and
patients, and miscellaneous in 3
patients. The miscellaneous eti-
ologies in both groups were as follows: ankylosing spondy-
litis (n  2), syphilis (n  2), systemic lupus erythematosus
(n  1), myxomatous proliferation of the aortic valve (n 
), rheumatoid arthritis (n 1), quadricuspid valve (n 1), and
Crohn’s disease (n  1).
The underlying mechanism of AR was: degenerative
(with valve thickening, annular enlargement, and central
defect) (n  137), bicuspid (n  111) (incomplete closure
with [n  41] or without prolapse [n  70]), rheumatic
Abbreviations
and Acronyms
AR  aortic regurgitation
BNP  B-type natriuretic
peptide
CHF  congestive heart
failure
CI  confidence interval
EDD  end-diastolic
diameter
EDD/BSA  end-diastolic
diameter indexed according
to body surface area
EF  ejection fraction
EROA  effective
regurgitant orifice area
ESD/BSA  end-systolic
diameter indexed according
to body surface area
HR  hazard ratio
IDI  integrated
discrimination improvement
IQR  interquartile range
LV  left ventricular
LVD  left ventricular
dysfunction
LVDSD  left ventricular
systolic dysfunction
symptoms or death
MET  metabolic
equivalent
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
OR  odds ratio
PWTd  posterior wall
thickness in diastole
PWTs  posterior wall
thickness in systole
ROC  receiver-operator
characteristic
RV  regurgitant volume
SBP  systolic blood
pressure
WS  wall stress(with fibrosis preventing cusp apposition with a defect in thecenter of the valve) (n  21), post-endocarditis (n  16)
(infection causing leaflet destruction or perforation in 10
patients), vegetation interfering with proper coaptation
of the cusps (n  6), combined (n  7), and miscellaneous
(n  9).
We included patients fulfilling the following criteria:
1) chronic severe AR as determined by echocardiographic
measurement (EROA 30 mm2 and regurgitant volume
RV] 60 ml/beat) (14); 2) preserved exercise tolerance
efined by an exercise electrocardiogram performed with the
ruce protocol and the following requirements: functional
apacity 7 metabolic equivalents (METs) without symp-
oms (angina or dyspnea) or any of the following: complex
entricular arrhythmia, hypotension, or pathological ST
egment deviation; and 3) LVEF above 55% at rest. We
xcluded patients with associated valve disease (aortic ste-
osis with peak gradient 20 mm Hg, moderate or severe
itral regurgitation, hemodynamically significant mitral
tenosis, or significant right-sided organic valve disease),
revious valve or coronary surgery, aortic root enlargement
40 mm), aortic dissection or ongoing endocarditis, car-
iomyopathies or pericardial diseases, and a history of
oronary artery disease.
Follow-up was complete in all but 3 patients (2 patients
f the derivation set and 1 patient of the validation set).
linical data. At entry, complete clinical evaluation was
erformed in all patients. Decisions about valve surgery
ere left to the treating physicians, who were unaware of the
NP results.
chocardiographic data. All studies were performed with
ewlett Packard Sonos 5500 equipment (Andover, Massa-
husetts). Studies included a spectral, continuous, and color
oppler transthoracic echocardiographic examination in all
atients. The degree of AR was quantified according to the
lassical color Doppler parameters (14). LV volume and
VEF were measured by using Simpson’s biplane technique
15). EDD and ESD were indexed according to body
urface area (EDD/BSA and ESD/BSA) (16). Atrial vol-
me was indexed by body surface area; mean systolic WS
nd pulmonary artery systolic pressures were measured
lassically (17). We determined RV, regurgitant fraction,
nd EROA as averaged values measured with the quanti-
ative Doppler flow method and the proximal isovelocity
urface area method that analyzes proximal flow conver-
ence (18,19).
End-diastolic radius/thickness ratio was calculated as:
DD/(2  PWTd), where PWTd is posterior wall thick-
ess in end-diastole. A previous study (20) reported that this
ndex is linearly related to the LV volume/mass ratio, as a
easure of LV pre-load.
End-systolic circumferential WS, as a measure of LV
fterload, was calculated as: (0.334  SBP  LVDs)/
(PWTs [1  PWTs/LVDs]) (kdyne/cm2), where SBP is
systolic blood pressure and PWTs is posterior wall thickness
in systole (21).
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October 11 2011:1705–14 BNP in Asymptomatic Severe Aortic RegurgitationThe echocardiographic readings were conducted by 2
independent observers who were blinded to the clinical and
biochemistry information.
Biochemistry data. Blood samples were obtained in all
patients 24 h after enrollment in the echocardiography
laboratory and then repeated 1 year later. Venous blood
samples were obtained on usual medications with the
patient resting quietly while semirecumbent. The samples
were placed immediately on ice, and plasma was stored at
–80°C before being assayed for BNP using standard radio-
immunoassay (22). The samples were obtained by techni-
cians blinded to the clinical and echocardiographic data. All
BNP measurements were carried out at the same time.
Endpoint definition. The combined endpoint consisted of
the appearance of either CHF or LVD, or left ventricular
systolic dysfunction symptoms or death (LVDSD) during
follow-up. The presence of CHF was defined as the onset of
dyspnea in New York Heart Association functional class III
and IV requiring initiation of sustained pharmacologic
treatment. New onset of LVD was defined as the assess-
ment of an LVEF below 55% during follow-up (1,23,24)
that was not present at baseline.
All outcomes were assessed by 2 investigators blinded to
the echocardiographic and clinical data. Patients referred for
surgery without symptoms or low EF (because of physician
preferences) were counted as not reaching an endpoint in
the analysis, and these cases were censored.
Follow-up. Clinical and echocardiographic evaluations
were performed at least yearly during a follow-up visit.
Patients who died or underwent surgery were censored
the same day and all others were censored at the end of
follow-up.
Statistical analysis. All results for continuous variables are
expressed as mean SD, and skewed variables are expressed as
edian (25% to 75% interquartile range [IQR]). For group-
ise comparisons of continuous variables, the Mann-Whitney
test and Student t test were used for skewed and normally
distributed variables, respectively. For categorical variables, the
Fisher exact or chi-square tests were used. The cutoff level for
each variable was set according to the receiver-operator char-
acteristic (ROC) analysis. The cutoff level for BNP was set
according to the ROC curve. The BNP value showing the
maximum likelihood ratio in the curve was established as the
cutoff point between low and high BNP. This cutoff point was
prospectively tested in the validation set.
Survival analysis was assessed using the Kaplan-Meier
method. Nonadjusted comparison of time to the event was
based on the log-rank test. Logistic regression multivariate
analysis was developed to analyze the effect of clinical and
echocardiographic variables on the observed association
between basal BNP levels and the risk of the combined
endpoint. For the assessment of linearity, we grouped BNP
concentrations and the echocardiographic variables into
quartiles. We then fitted a regression model for the predic-
tion of the combined endpoint, with the lowest quartile
serving as the reference group, and plotted the average valueof each quartile versus the coefficient of the quartile. The
plot was then examined with respect to the shape of the
resulting curve. Variables showing lack of linearity were
logarithmically transformed.
The multivariate regression models incorporated clinical
and echocardiographic variables that proved to be related to
the combined endpoint on univariate analysis. To assess the
statistical significance of BNP values, we adjusted the p
values using the Bonferroni correction, dividing the usual p
value (0.05) by the number of variables in the model.
To facilitate the clinical interpretation, we repeated the
multivariate analysis, entering BNP and the echocardio-
graphic measurements as dichotomous variables with the
cutoff points that were previously described.
Comparison between ROC curves was performed with
the ROC analyzer program, Stata version 10.0 (Stata
Corporation, College Station, Texas).
To assess the usefulness of BNP, we determined the
integrated discrimination improvement (IDI), absolute and
relative, to quantify the increase in separation of events and
nonevents as determined by Pencina et al. (25). The
statistical analysis was performed with Stata version 10.0
(Stata Corporation, College Station, Texas). A p value
0.05 was considered significant, and all of the tests
performed were 2-tailed.
Results
Baseline characteristics. A total of 294 patients were
included, 160 in the derivation cohort and 134 in the
validation cohort. Median BNP values at entry were similar
in both sets: 31 (IQR: 7 to 244) and 35 (IQR: 9 to 234) in
the derivation and validation cohorts, respectively.
The characteristics of both sets of 294 patients were as
follows: age 53  9 years; 165 patients (56%) were male;
138 had prior hypertension (47%); median EF was 0.65
(IQR: 0.61 to 0.72); median EDD/BSA was 40 (IQR: 28 to
44); median EDS/BSA was 18 (IQR: 13 to 27); median
EROA was 48 (IQR: 39 to 78); and median RV was 79
(IQR: 63 to 101).
Events. In the derivation set, 45 patients (28%) suffered
LVDSD. Three patients (1.9%) died; it was sudden in 2
patients and caused by congestive heart failure in 1 patient.
New CHF was diagnosed in 29 patients (18%). Among
these 29 patients, 22 required the initiation of sustained
pharmacologic treatment for CHF, including 7 patients
who required hospitalization for the same reason. Fifteen
patients (9.4%) developed LVD. Seven patients (4.3%) had
new-onset atrial fibrillation and 15 patients (9.4%) devel-
oped pulmonary hypertension. Mean follow-up of the
derivation set was 46  10 months.
Aortic valve surgery was performed in 50 (31%) patients
at follow-up. Forty-four patients underwent surgery because
of CHF or LV systolic dysfunction. The median BNP value
in patients who underwent surgery was 139 (IQR: 90 to
209) versus 42 (IQR: 15 to 89) in patients without surgery.
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BNP in Asymptomatic Severe Aortic Regurgitation October 11 2011:1705–14Six patients did not reach the combined endpoint but
underwent surgery, as indicated by their referring physician.
These patients were not significantly different from patients
who reached the combined endpoint in terms of their
clinical and echocardiographic variables. The BNP values in
this subset of 6 patients were median 31 pg/ml (IQR: 11 to
105 pg/ml).
In the validation set, 35 patients (26%) developed
LVDSD. Two patients (1.5%) died; it was sudden in 1
patient and noncardiac related in the other. In addition, 26
patients (19.4%) developed CHF (17 patients received
sustained pharmacologic treatment for CHF and 9 patients
were hospitalized for the same reason). Finally, 14 patients
(10.4%) developed LVD. Mean follow-up in the validation
set was 38  9 months. Five patients (3.7%) experienced
new-onset atrial fibrillation, and 12 patients (9.0%) devel-
oped pulmonary hypertension during follow-up.
Aortic valve surgery was performed in 39 patients (29.1%)
of the validation set. The BNP value in patients who
underwent surgery was 137 (IQR: 93 to 210) versus 45
(IQR: 11 to 83) in patients without surgery. Seven patients
did not reach the combined endpoint but underwent sur-
gery, as indicated by their referring physician. These pa-
tients were not significantly different with regard to clinical
and echocardiographic variables from patients who reached
the combined endpoint, and the median BNP value in these
7 patients was 36 (IQR: 11 to 99).
Predictive value of BNP. UNIVARIATE ANALYSIS. The me-
ian BNP values were higher in patients who suffered
VDSD, in both the derivation (149 [IQR: 92 to 217] vs.
8 [IQR: 17 to 83], p  0.001) and the validation (141
IQR: 87 to 210] vs. 42 [IQR: 12 to 79], p  0.001) sets.
When we stratified BNP levels according to quartiles
35, 36 to 79, 80 to 129, and130 pg/ml), in the derivation
et patients’ event-free survival at 60 months was as follows:
9  4%, 96  7%, 90  6%, and 34  8%, respectively
p  0.0001).
The areas of the ROC curves relating baseline BNP levels to
he combined endpoint were 0.84  0.06 and 0.82  0.05
n the derivation and validation cohorts, respectively. From the
OC curve of the derivation set, we were able to derive an
ptimal cutoff value of 130 pg/ml. The highest likelihood ratio
orresponding to that value was 5.8 (95% confidence interval
CI]: 2.6 to 11.6). In the ROC curve of the validation set, a
NP value of 130 pg/ml was also associated with the best
ikelihood ratio of the combined endpoint.
Baseline characteristics of patients according to BNP
evels at admission are compared in Table 1. No significant
ifferences were observed in either set in terms of age, sex,
ypertension, atrial fibrillation, or heart rate. All parameters
elated to the amount of AR—such as RV, regurgitant
raction, and EROA—were also significantly higher in
atients with elevated BNP in the derivation set, as well as
n the validation set.
In the Kaplan-Meier analysis, BNP values were dicho-omized at this cutoff point and allowed to discriminate Eatients with higher risk of LVDSD in the derivation set
log-rank test 11.7; adjusted hazard ratio [HR]: 6.7 [95%
I: 2.3 to 15.6], p  0.0001) and also in the validation set
(log-rank test 12.2; adjusted HR: 6.54 [95% CI: 2.2 to
16.3], p  0.0001) (Figs. 1A and 1B).
Applying this cutoff value, sensitivity, specificity, negative
predictive value, and positive predictive value to predict
LVDSD in the derivation set were 78%, 93%, 91%, and
83%, respectively, while in the validation set values were
77%, 94%, 91%, and 81%, respectively.
Table 2 shows the relationship between baseline variables
and prognosis. In both sets, univariate markers of worse
evolution were BNP, ESD/BSA, EDD/BSA, EROA, atrial
volume indexed by body surface area, age, pulmonary artery
systolic pressures, EF, and LV volumes. Neither the mech-
anism of the AR nor the medical treatments were associated
with the outcome.
MULTIVARIATE ANALYSIS. In the derivation set, all variables
ignificantly associated with the endpoint were included in a
ogistic regression analysis. In our first model, we used log
ransformation of the continuous variables. In the derivation
ohort, the independent predictors were: BNP (odds ratio
OR]: 6.89 [95% CI: 2.52 to 17.57], p  0.0001), ESD/
BSA (OR: 3.14 [95% CI: 1.82 to 15.92], p  0.01), and
EROA (OR: 3.87 [95% CI: 2.27 to 16.45], p  0.001).
According to this model, the absolute and relative IDI of
the variables were as follows: BNP, 0.091078 and 0.198 (p
 0.00001); ESD/BSA, 0.058237 and 0.083 (p  0.001);
and EROA, 0.078125 and 0.117 (p  0.0001).
When we entered all markers in the multivariate model as
categorical variables, BNP 130 pg/ml was the strongest
ndependent predictor of symptoms, LVD, and/or death (OR:
.9 [95% CI: 2.52 to 17.57], p 0.0001). Other independent
rognostic variables were: ESD/BSA 24 mm/m2 (OR: 3.4
[95% CI: 1.88 to 11.9], p  0.01); and EROA 50 mm2
(OR: 4.3 [95% CI: 2.4 to 12.4], p 0.001) (Table 3). In
addition, BNP 130 pg/ml was the strongest predictor of
isolated LVD (OR: 6.6 [95% CI: 2.3 to 22.4], p  0.0001).
nother independent predictor of LVD was an EROA 50
m2 (OR: 4.9 [95% CI: 2.1 to 27.7], p  0.001).
In the validation set, multivariate analysis determined that
he following variables were independent predictors: BNP
130 pg/ml (OR: 6.7 [95% CI: 2.9 to 16.9], p  0.0001),
ROA50 mm2 (OR: 4.3 [95%CI: 2.6 to 13.5], p 0.001);
nd ESD/BSA 24 mm/m2 (OR: 3.4 [95% CI: 1.7 to 14.7],
p  0.02). According to this model, the absolute and
relative IDI of the variables were: BNP, 0.089174 and
0.187 (p  0.00001); ESD/BSA, 0.053139 and 0.078 (p 
0.001), and EROA, 0.076457 and 0.115 (p  0.0001). BNP
130 pg/ml was the strongest predictor of isolated LVD (OR:
6.2 [95% CI: 2.5 to 27.3], p  0.0001). Another independent
predictor of LVD was EROA 50 mm2 (OR: 4.8 [95% CI:
.2 to 29.4], p  0.001).
The addition of BNP to the non-BNP model (EROA,
SD/BSA, and EDD/BSA) significantly increased the area
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October 11 2011:1705–14 BNP in Asymptomatic Severe Aortic Regurgitationunder the ROC curve from 0.82 to 0.92 (p  0.01) in the
erivation set, and from 0.80 to 0.89 (p  0.01) in the
alidation set (Fig. 2A and 2B). The combination of BNP
nd EROA information in the derivation set is depicted in
igure 3. For comparison, values corresponding to the
ombination of EROA 50 mm2 and BNP 130 pg/ml
ere chosen as the reference group. As shown, the associ-
tion of BNP levels 130 pg/ml and EROA 50 mm2
entailed the worst prognosis. Among these patients,
24 (88%) had LVSD (HR: 4.7 [95% CI: 2.6 to 15.8], p 
0.0001 vs. reference group). Of note, of the 3 deaths
observed in the study, 2 occurred in this subgroup.
Serial BNP measurements. Patients who reached an end-
point had a higher rate of increase in BNP levels at 1 year
than patients with an uneventful course (derivation set 29
10 pg/ml vs. 10  6 pg/ml, p 0.0001; validation set 31 
Basal Characteristics in Relation to BNP LevelsTable 1 Basal Characteristics in Relation to BNP Levels
Derivation Set
Characteristic
BNP <130 pg/ml
(n  118)
BNP >13
(n 
Age (yrs) 51 9 56
Male (%) 65 (55) 24 (57)
AF (%) 5 (4) 3 (7)
Hypertension (%) 64 (54) 17 (40)
SBP (mm Hg) 139 37 136
Diastolic blood pressure (mm Hg) 61 12 56
Heart rate (beats/min) 76 10 69
Exercise capacity (METs) 9.5 (8.5–15) 8.5 (8.0
Heart-rate product (1,000) at
peak exercise test
22.4 (18.7–25.8) 21.8 (17.
SBP (mm Hg) at peak exercise 174 (135–198) 171 (138
Heart rate (beats/min) at peak exercise 121 (97–144) 119 (94–
EF (%) 64 (57–71) 61 (56–
EDV (ml/m2 ) 97 (56–107) 125 (69–
ESV (ml/m2 ) 27 (17–34) 35 (24–
Fractional shortening (%) 38 (33–44) 35 (31–
EDD/BSA (mm/m2) 30 (27–36) 42 (28–
ESD/BSA (mm/m2) 16 (12–21) 26 (18–
R/T 2.35 (1.7–2.6) 2.52 (1.9
WS (kdyne/cm2) 64.4 (37.4–73.1) 73.2 (42.
RV (ml/beat) 74 (63–90) 87 (69–
RF (%) 59 (53–77) 69 (59–
EROA (mm2) 44 (35–69) 57 (41–
AV/BSA (cm3/m2) 57 (37–68) 65 (48–
PASP (mm Hg) 25 (18–31) 33 (22–
Medical treatment during the study (%)
ACE-I 68 (57) 21 (50)
ARB 27 (23) 11 (26)
CCB 19 (16) 7 (17)
AA 5 (4.2) 2 (4.7
BB 6 (5) 2 (4.7
Digoxin 3 (2.5) 1 (2.4
Values are mean  SD, absolute numbers (%), or median (Interquartile range).
AA  aldosterone antagonists; ACE-I  angiotensin-converting enzyme inhibitors; AF  atrial
beta-blockers; BNP  B-type natriuretic peptide; CCB  calcium-channel blockers; EDD/BSA  e
effective regurgitant orifice area; ESD/BSA  end-systolic diameter/body surface area; METs 
end-diastolic radius/thickness ratio; RV  regurgitant volume; SBP  systolic blood pressure; WS7 pg/ml vs. 9  4 pg/ml, p  0.001).Among patients with baseline BNP values 130 pg/ml,
4 (2.5%) exhibited a BNP elevation above that level at 1 year in
the derivation set, and 3 patients (2.2%) did so in the validation
set. All of these patients had LVDSD at follow-up.
By Kaplan-Meier analysis, patients with an increased BNP
130 pg/ml at 1 year had a worse outcome than patients who
persisted with BNP 130 pg/ml (log-rank test 16.2; adjusted
HR: 7.6 [95% CI: 4.2 to 19.6], p  0.0001). Similar findings
were observed in the validation set (log-rank test 15.8; adjusted
HR: 8.6 [95% CI: 3.5 to 19.8], p  0.0001).
Discussion
In this population of asymptomatic patients with severe AR
and normal LV systolic function, baseline BNP level was a
strong independent prognostic marker. Our study also
Validation Set
l
p Value
BNP <130 pg/ml
(n  100)
BNP >130 pg/ml
(n  34) p Value
0.07 52 9 57 8 0.08
0.11 54 (54) 18 (52) 0.94
0.04 4 (4) 2 (6) 0.045
0.19 55 (55) 14 (42) 0.16
0.58 136 21 135 25 0.91
0.48 59 10 55 12 0.56
0.21 78 10 72 12 0.37
0.37 10 (8.0–14) 8.5 (7.5–13.5) 0.15
) 0.61 21.9 (17.8–25.7) 20.8 (17.4–24.9) 0.49
0.77 176 (137–209) 172 (139–205) 0.64
0.81 123 (96–147) 120 (94–142) 0.87
0.035 65 (58–70) 62 (57–65) 0.04
0.03 95 (55–105) 119 (61–136) 0.025
0.02 25 (18–32) 34 (22–39) 0.02
0.06 39 (34–46) 35 (32–37) 0.056
0.001 32 (28–37) 40 (31–45) 0.01
0.001 15 (13–22) 24 (20–27) 0.001
) 0.02 2.38 (1.65–2.55) 2.49 (1.87–3.07) 0.03
) 0.02 63.1 (38.4–71.2) 71.4 (40–81.3) 0.03
0.01 76 (62–91) 91 (69–105) 0.01
0.01 61 (53–76) 70 (56–88) 0.01
0.0001 45 (34–66) 62 (48–91) 0.001
0.02 54 (34–62) 63 (39–79) 0.04
0.035 23 (15–29) 34 (21–42) 0.025
0.21 50 (50) 16 (47) 0.69
0.47 23 (23) 7 (20) 0.52
0.93 16 (16) 6 (18) 0.71
0.77 4 (4) 1 (3) 0.74
0.87 4 (3) 1 (3) 1.00
0.82 2 (2) 1 (3) 0.56
tion; ARB  angiotensin II receptor blocker; AV/BSA  atrial volume/body surface area; BB 
tolic diameter/body surface area; EDV  end-diastolic volume; EF  ejection fraction; EROA 
olic equivalents; PASP  pulmonary artery systolic pressure; RF  regurgitant fraction; R/T 
-systolic circumferential wall stress.0 pg/m
42)
10
21
14
11
–12.5)
9–24.7
–194)
141)
65)
143)
40)
39)
47)
30)
1–3.11
7–83.6
107)
84)
84)
75)
40)
)
)
)
fibrilla
nd-diasconfirmed that in this type of patient, echocardiographic
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predictors of adverse outcome. However, according to our
results, BNP was of greater prognostic value than ESD or
EROA, and contributed independent prognostic informa-
tion in additional to that provided by these echocardio-
graphic parameters. As shown, after the addition of BNP to
the echocardiographic model, the area under the ROC
curve increased significantly both in the derivation and the
validation sets. Furthermore, we determined and validated
an optimal cutoff point for BNP of 130 pg/ml, thereby
identifying asymptomatic patients with severe AR and
preserved LV systolic function who are at higher risk. In our
study, BNP 130 pg/ml predicted a worse outcome with
additional information barely affected by the adjustments
Figure 1 Patient Risk of LVDSD According to BNP Levels
(A) Derivation set; (B) validation set. BNP  B-type natriuretic peptide; CI  confi
LVDSD  left ventricular systolic dysfunction symptoms or death.for EDD, ESD, WS, and EROA. Another point toconsider is the value of the repeated measurements of BNP.
Patients with a greater BNP increase at 1 year had a worse
subsequent course.
According to these data, the average time elapsed be-
tween the finding of an elevated BNP and the events was 15
months. Hence, the clinical application of this criterion to
avoid exposing the patient to the greater risk of the
pre-symptomatic phase would imply anticipating the surgi-
cal indication in approximately 2 years.
As stated by current guidelines (1,3), patients with severe
AR complicated with heart failure or LV systolic dysfunc-
tion should be promptly referred for surgical treatment.
Alternatively, clinical surveillance with frequent reassess-
ment is the preferred therapeutic strategy for asymptomatic
interval; HR  hazard ratio;dencepatients with preserved LV function (1,3). However, the
sympt
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sideration (2,4,7). First, early surgery may prevent sudden
death, which occurs in about 1% of cases. Second, early
surgery may prevent the development of CHF or LV
systolic dysfunction (2,6–8). This latter point is important
because the presence of such complications is associated
with a worse perioperative and post-operative outcome
(2,5,24,25).
Although the early intervention is theoretically attractive,
experience with this strategy is still scarce, probably due to the
lack of strong prognostic markers that allow for identification
of potential candidates for early surgery. In asymptomatic
patients, previous studies have shown that echocardiographic
parameters reflecting ventricular size and volume overload
(EDD, ESD, and end-systolic volume), WS, and the EROA
may identify patients who will be at greater future risk
(7,26,27). The prospective studies of AR natural history with
an average follow-up of 7 to 8 years found that systolic phase
descriptors measured at rest and during exercise predicted heart
failure, subnormal LVEF at rest, and sudden death (4,5,26). In
addition, other important determinants of prognosis include
EDD and stress-normalized LV performance (26,27).
However, according to our data, a marker of myocardial
stress such as BNP is able to discriminate prognosis better
than the echocardiographic parameters associated with the
magnitude of volume overload or changes in resting systolic
Univariate Predictors of LVDSDTable 2 Univariate Predictors of LVDSD
Derivation Set
Characteristic OR (95% CI)
Age 60 yrs 1.9 (1.4–7.2)
EF 60% 2.0 (1.27–11.8)
EDV/BSA 90 ml/m2 1.75 (1.05–12.5)
ESV/BSA 35 ml/m2 2.1 (1.3–10.1)
Fractional shortening 35% 1.97 (0.78–6.74)
AF 1.98 (0.89–8.9)
BNP 130 pg/ml 6.6 (2.9–16.6)
EDD/BSA 35 mm/m2 2.2 (1.7–14.3)
ESD/BSA 24 mm/m2 3.6 (2.1–10.4)
R/T 2.15 1.5 (1.02–7.8)
WS 65 kdyne/cm2 1.98 (1.24–8.6)
RV 75 ml/beat 2.7 (1.3–10.2)
EROA 50 mm2 4.4 (2.2–10.7)
AV 60 cm3/m2 2.4 (1.7–11.2)
PASP 35 mm Hg 1.92 (1.47–9.47)
CI  confidence interval; LVDSD  left ventricular systolic dysfunction
Multivariate Analysis to Predictthe Combined Endpoint: Deriva ion SetTable 3 Multivar a e Analys s to Predictthe Combined Endpoint: Derivation Set
Endpoint OR (95% CI) p Value
BNP 130 pg/ml 6.9 (2.52–17.57) 0.0001
ESD/BSA 24 mm/m2 3.4 (1.88–11.9) 0.01
EROA 50 mm2 4.3 (2.4–12.4) 0.001
EDD 35 mm/m2 2.1 (0.88–13.7) 0.09Abbreviations as in Tables 1 and 2.function, suggesting that BNP is not merely a surrogate of
the volume overload imposed by the AR.
Which are the mechanisms responsible for the prog-
nostic significance of elevated BNP in this particular
group of patients? Experimental and clinical data rein-
force the hypothesis that higher BNP levels in patients
with preserved LV function at rest could represent
subclinical ventricular dysfunction (28,29). Thus, these
data led us to speculate that elevations of this peptide in
asymptomatic patients may indicate the presence of
subtle myocardial impairment elicited by longstanding
volume and pressure overload in AR.
There are only few data available regarding the prognostic
value of natriuretic peptides in chronic AR (12,13). One
study found that NT-proBNP was increased in conserva-
tively treated patients and decreases after successful surgical
therapy. The same study also underlines the consistent
relation of NT-proBNP level with the severity of the
aortic valve defect (12). In another study (13), natriuretic
peptides (BNP and NT-proBNP) were higher in symp-
tomatic than in asymptomatic patients but with a weak
correlation of both markers with the echocardiographic
measures of LV size and function (EDD, ESD, end-
systolic volume, end-diastolic volume, LV systolic WS,
and left atrial size).
Study limitations. In this study, functional capacity was
assessed using an electrocardiographic exercise test.
Other tests may be more accurate for this analysis, such as
an exercise test with simultaneous measurement of myo-
cardial oxygen consumption; however, current guidelines
do not mention its usefulness (1,3). We also believe that
the lack of tissue Doppler measurements and of an
exercise stress echocardiogram may be considered a
160) Validation Set (n  134)
p Value OR (95% CI) p Value
0.02 1.4 (1.1–8.2) 0.04
0.036 2.1 (1.21–12.8) 0.035
0.045 1.7 (1.1– 13.4) 0.04
0.031 2.05 (1.32–12.4) 0.027
0.21 1.84 (0.81–7.1) 0.34
0.062 2.0 (0.93–9.4) 0.058
0.0001 6.7 (2.4–17.3) 0.0001
0.01 2.0 (1.5–13.4) 0.02
0.001 3.4 (1.7–11.5) 0.001
0.05 1.64 (1.3–8.9) 0.04
0.03 2.15 (1.41–9.78) 0.025
0.01 2.4 (1.2–13.1) 0.03
0.0001 4.3 (2.4–11.7) 0.0001
0.01 2.3 (1.3–14.1) 0.02
0.03 1.7 (1.27–10.2) 0.035
oms or death; OR  odds ratio; other abbreviations as in Table 1.(n limitation of this study (30).
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BNP in Asymptomatic Severe Aortic Regurgitation October 11 2011:1705–14These results are not conclusive, and a randomized, con-
trolled study between patients with early versus deferred study
between patients with early versus deferred surgery stratified
according to BNP level is needed to assess the clinical value
and the cost/benefit implications of this strategy. Finally, we
should mention that the model could be overfitted when
applied to the validation set.
Conclusions
Careful clinical assessment and surveillance are mandatory
Figure 2 ROC Analysis: Incremental Value of BNP When Added
EDD/BSA  end-diastolic diameter indexed according to body surface area; EROA
ing to body surface area; LVDSD  left ventricular systolic dysfunction, symptomsin asymptomatic patients with severe AR and preserved LVfunction. Because of its strong independent and incremental
prognostic value, BNP assessment—integrated with echo
parameters of LV performance—should be considered in
the clinical routine workup for risk stratification of patients
with severe AR who are free of symptoms or LVD.
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